Live
- Pakistan Protests: PTI Supporters March Towards Islamabad, Demanding Imran Khan's Release
- Additional Collector Conducts Surprise Visit to Boys' Hostel in Wanaparthy
- Punjab hikes maximum state-agreed price for sugarcane, highest in country
- Centre okays PAN 2.0 project worth Rs 1,435 crore to transform taxpayer registration
- Punjab minister opens development projects of Rs 120 crore in Ludhiana
- Cabinet approves Atal Innovation Mission 2.0 with Rs 2,750 crore outlay
- Centre okays Rs 3,689cr investment for 2 hydro electric projects in Arunachal
- IPL 2025 Auction: 13-year-old Vaibhav Suryavanshi becomes youngest player to be signed in tournament's history
- About 62 lakh foreign tourists arrived in India in 8 months this year: Govt
- IPL 2025 Auction: Gujarat bag Sherfane Rutherford for Rs 2.60 cr; Kolkata grab Manish Pandey for Rs 75 lakh
Cipla gets USFDA nod for its abbreviated New Drug Application
Cipla Limited (File/Photo)
Drug firm Cipla Limited on Thursday, August 12, 2021, announced that it has received final approval from the US health regulator for its Abbreviated New Drug Application (ANDA) for Difluprednate Ophthalmic Emulsion 0.05%.
Drug firm Cipla Limited on Thursday, August 12, 2021, announced that it has received final approval from the US health regulator for its Abbreviated New Drug Application (ANDA) for Difluprednate Ophthalmic Emulsion 0.05%.
CIPLA in a regulatory filing said that it has received approval from the United States Food and Drug Administration (US FDA) to market its product which is a generic version of Novartis Pharmaceuticals Corporation Durezol® (Difluprednate Ophthalmic Emulsion 0.05%).
Cipla's Difluprednate Ophthalmic Emulsion 0.05% is AB-rated generic therapeutic equivalent version of Novartis Pharmaceutical Corporation's Durezol®.
It is used for the following:
• Treatment of inflammation and pain associated with ocular surgery.
• Treatment of endogenous anterior uveitis.
According to IQVIA (IMS Health), Durezol® had US sales of approximately $106mn for the 12 months ending June 2021. The product will be available for shipping soon.
Shares of Cipla were trading 0.44 per cent down at Rs 905.85 apiece at 2:58 pm on the NSE.
